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c o r e t v a s a 5 4 ( 2 0 1 2 ) e 3 3 9 – e 3 4 0Editorial—Special issue: Atrial FibrillationAtrial fibrillationFor the end of the year 2012, we have prepared a special issue
of Cor et Vasa devoted to atrial fibrillation (AF). Management
of atrial fibrillation is one of the most rapidly developing
areas of arrhythmia services, in particular because of better
outcomes of catheter ablation and innovative approaches to
the prevention of thromboembolic complications of AF. Fol-
lowing my graduation from a medical school, I started a long-
term internship at the 1st Department of Internal Medicine,
General University Hospital in Prague. During ward rounds
led by Professor Kordacˇ, atrial fibrillation was considered
arrhythmia of the elderly and not much was done about it,
apart from attempted cardioversion with the available anti-
arrhythmic drugs or rhythm control with digoxin and anti-
platelet therapy, which at that time was not indicated in all
at-risk patients.
Ten years later, in 1996, I had an opportunity to participate
in a Rome symposium on arrhythmias. There, before their
well-known article was published, our colleagues from Bor-
deaux presented, for the first time, results of their innovative
study that detected triggers of paroxysmal atrial fibrillation
mostly in openings of the pulmonary veins and in numerous
anatomical structures of the left and right atria. This was the
actual beginning of catheter ablation for atrial fibrillation. The
techniques developed from ostial ablations of AF triggers and
large antral lesions using a traditional electrophysiological
approach, 3D mapping with possible integration of the recon-
structed left atrium from computed tomography or magnetic
resonance imaging, to complex robotic systems currently
used in three Czech centers with the aim of improving theFig. 1 – Profile of arrhythmia ablationeffectiveness, safety and complexity of procedures. The good
news is that catheter ablation has been increasing in number
and that in 2011, the Czech Republic ranked seventh (156
procedures per 1 million population), as stated by the EHRA
White Book [1]. In the same year, atrial fibrillation ablation
accounted for nearly 37% of all interventions (Fig. 1).
Given the number of individuals with atrial fibrillation in
the Czech Republic (an estimated 200,000 potential patients),
the treatment of choice in most cases continues to be
antiarrhythmic and anticoagulation therapy. For many years,
no substantial changes have occurred in these two key
segments. Recently, the therapy has been modified to use
new molecules already incorporated into the new Czech
Society of Cardiology treatment guidelines for atrial fibrilla-
tion [2] and 2012 update of the European Society of Cardiology
guidelines [3]. Therefore, this special issue of Cor et Vasa is a
platform where an abridged version of the European recom-
mendations are published by the Arrhythmias and Perma-
nent Cardiac Pacing Working Group. It was a pleasure to see
this year’s consensus of most influential European, American
and other societies on recommendations for selection, man-
agement and follow up of patients with catheter ablation of
AF [4]. At the same time, the EHRA Scientific Initiative
Committee published an article on monitoring in the man-
agement of patients with AF [5].
At least in the European context, the Czech Republic is
among countries with an advanced approach to managing atrial
fibrillation, excellent outcomes even in patients with chronic
arrhythmia, and very good prevention of thromboembolictherapy in Czech Republic (2011).
E d i t o r i a l / c o r e t v a s a 5 4 ( 2 0 1 2 ) e 3 3 9 – e 3 4 0e340complications, especially at the level of specialized compre-
hensive cardiology centers offering individualized care, the
most adequate therapy and the best results.
The only unresolved problem is the long-term effectiveness
of catheter ablation for permanent atrial fibrillation, particu-
larly in patients with alteration of myocardial structure.
The first studies using a hybrid approach (a combination of
minimally invasive primarily surgical and catheter intravas-
cular ablation) have shown possible trends in the develop-
ment of these issues.
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